For Cogent Biosciences Inc. (COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, 2026 is shaping up to be a pivotal year as its lead drug candidate Bezuclastinib approaches multiple regulatory and clinical milestones.
Bezclastinib is a potent type-1 tyrosine kinase inhibitor that blocks mutant KIT D816V activity while sparing other kinases, thereby minimising the potential for off-target side effects. KIT mutations serve as driver mutations in up to 80% of gastrointestinal stromal tumors (GIST) and in over 90% of systemic mastocytosis.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.